SDZ.SW News | FINWIRES

Swiss Stocks Close Week Flat; US Fed Ends Actions Against UBS, Credit Suisse

The Swiss Market Index was up 0.05% on Friday's close amid a quiet day of local economic news following the Ascension Day holiday.Sandoz Group (SDZ.SW) secured marketing authorization from the European Commission for its insulin lispro biosimilar Bysumlog to treat diabetes mellitus in adults and children, while its insulin aspart biosimilar Dazparda was approved for the treatment of the same condition in adults, adolescents, and children aged one year and above. Both injectable biosimilars are comparable in efficacy and safety to their reference medicines. At closing, the Swiss pharmaceutical major's stock was 3.36% in the red.Meanwhile, Berenberg left Zurich Insurance Group's (ZURN.SW) buy rating and price target of 656 francs unchanged following its first-quarter trading update, noting the insurer's "attractive" valuation and better-than-expected growth in gross premiums in its non-life insurance segment. Zurich's shares closed the session 0.46% higher."This strong commercial non-life gross premium growth is noteworthy, as we believe that it was achieved at attractive margins; for example, pricing in North America commercial improved modestly from -1% in 2025 to 0% in Q1 2026. Zurich in its results also indicated that the 7% growth in the midmarket may accelerate in H2 2026, as the new mid-market underwriters in the US gain traction," the research firm said in a note. "We believe that this strong gross premium growth will lead to strong operating profit growth. We believe that the strong rise in Zurich's solvency ratio from 259% at FY 2025 to 265% at Q1 2026, ahead of 261% consensus, reflects part of the benefit of higher earnings."In other news, the US Federal Reserve Board terminated enforcement actions against UBS Group (UBSG.SW) and its Credit Suisse units, effective Tuesday. This relates to the consent order and $268.5 million fine issued by the Fed to the Swiss group in July 2023, due to Credit Suisse's "unsafe and unsound counterparty credit risk management practices" with Archegos Capital Management. UBS fell 0.69%.Looking ahead, the upcoming week will see the first-quarter data for Switzerland's economic growth and industrial production.

^SSMI$SDZ.SW$UBSG.SW$ZURN.SW

Asia Markets47d ago

Swiss Blue-chip Index Extends Losses; UBS Shares Up

Swiss stocks extended their losing streak at Wednesday's close, with the Swiss Market Index down 0.88%, as investors assessed fresh corporate and economic data releases while awaiting the US Federal Reserve's monetary policy decision.The Fed is widely expected to leave its key interest rate unchanged in the 3.5% to 3.75% range later today."Nothing much is expected from this meeting. The March dots showed the Committee median vote leaned toward one cut this year and one more next year. That's unlikely to be settled for a long while yet. [US Fed Chair] Powell is unlikely to be comfortable with teeing up such a move before his successor takes over and he faces eleven other voting FOMC members that are more worried about inflation at the moment," Scotiabank Economics said. "Our forecast remains for one cut by late year and another in early 2027 which would drop the fed funds upper limit rate to 3.25% and hence still on the boundary between restrictive and neutral."Back home, data from UBS & CFA Society Switzerland showed that the country's economic sentiment index increased to -30.3 points in April from -35 points in March.On the corporate front, Sandoz Group's (SDZ.SW) net sales increased to $2.76 billion in the first quarter from the year-ago $2.48 billion, bolstered by an 18% growth in constant-currency net sales at its biosimilars segment. For 2026, the Swiss pharmaceutical major reaffirmed its guidance of a mid-to-high single-digit percentage growth in net sales at constant currency. The stock closed the session 2.23% lower.On the flip side, UBS Group (UBSG.SW) gained 3.22% at closing as it delivered a year-over-year surge in first-quarter net profit attributable to shareholders to $3.04 billion from $1.69 billion. Total revenue also climbed over the period to $14.24 billion from $12.56 billion, mainly driven by double-digit growth in the Swiss banking group's core franchises."We delivered excellent financial results and remain on track to deliver on our financial objectives for 2026 ... Having now successfully transferred all client accounts in Switzerland, we achieved another crucial milestone in one of the most complex integrations in banking history. We are confident in substantially completing the integration by year-end, positioning us for further sustainable growth," Chief Executive Officer Sergio Ermotti said. "On the topic of Swiss capital requirements, we will continue to engage constructively and contribute to fact-based deliberations. These developments do not, and will not, change who we are as a firm."

^SSMI$SDZ.SW$UBSG.SW